Web search on "other AI-bio / model-provider / Illumina-like names" surfaced two material things:

(1) The IPO gate (domino #1) is HALF-OPEN, not shut. 2026 has a live biotech IPO wave: Kailera $625M (record), Generate Biomedicines/GENB $400M (Feb 26, AI protein design — Flagship, the same lab family as Lila), Eikon $381M (AI+automation), Aktis $318M (AI radiopharma), Alamar/proteomics $220M (Apr). BUT aftermarket is soft (GENB & Eikon fell on debut) and XBI is still weak-down (RSI 45). So: issuance window open, equity appetite lagging. Refined domino #1 from 🔴 shut → 🟠 half-open. The disciplined read that STRENGTHENS the picks-and-shovels case: biotechs are raising cash NOW → they spend it on reagents/CROs/instruments regardless of where their own equity trades, so the fundamental dominoes (2–5) get fed even while the sentiment gauge (XBI) lags. Sources: BioPharma Dive / BioSpace / Fortune / Xtalks IPO trackers (2026).

(2) The AI "model-provider" layer is almost entirely PRIVATE. EvolutionaryScale, Chai Discovery, Cradle, Inceptive, Basecamp Research, Boltz, Earendil ($787M Mar 2026), Profluent, Dyno, Terray, NOETIK; Anthropic acquired Coefficient Bio ($400M, Apr 2026). Public ways to touch it: NVDA (BioNeMo — hosts 200+ techbios' models, the arms dealer), GOOGL (Isomorphic), and the public AI-platform names (GENB/ABCL/RXRX/SDGR/TEM/CERT).

Coverage gaps found (not in any watchlist): GENB, CERT (Certara, biosimulation software), SLP (Simulations Plus, biosimulation), QSI (Quantum-Si), SEER, QTRX (Quanterix), LAB (Standard BioTools), ALMR (Alamar), NAUT (Nautilus). ABCL (AbCellera) is in holdings-stocks — user OWNS it — but NOT yet in this lane's watchlist (should cross-list). Noted-not-added: ONT (Oxford Nanopore, foreign primary), AKYA (verify Quanterix merger status), EIKN (clinical-stage drug co, not a tool).

RESOLVED — roster expanded 24→28 (user chose "core" add). Added ABCL/GENB/CERT/SLP, fetched + precomputed + verified clean (28/28). ABCL added to key_tickers (user holding + clean AI-antibody platform). Tape on the 4: ABCL RSI 67 +77% 3m strong-up (already ripped — the winner), GENB RSI 56 neutral +18% 3m but below $16 IPO (early), CERT RSI 51 −21.5% 3m strong-down −60% off high (deep washout — biosimulation value but a falling knife, wait for it to stop going down), SLP RSI 60 +34% 3m recovering. Bifurcation holds inside the adds too. Proteomics frontier (QSI/SEER/QTRX/LAB/ALMR/NAUT) left noted-not-added per the core-only choice. README L1/L1b/L3b + key-tickers/routing + ACTIVE.json thesis/key_tickers all updated.